Related references
Note: Only part of the references are listed.Time-to-infection by Plasmodium falciparum is largely determined by random factors
Mykola Pinkevych et al.
BMC MEDICINE (2015)
Post-treatment control of HIV infection
Jessica M. Conway et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation Report of 2 Cases
Timothy J. Henrich et al.
ANNALS OF INTERNAL MEDICINE (2014)
A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy
Adam M. Spivak et al.
CLINICAL INFECTIOUS DISEASES (2014)
HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
Nancy M. Archin et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Towards a cure for HIV-are we making progress?
Sharon R. Lewin et al.
LANCET (2014)
Persistence by proliferation?
David Margolis et al.
SCIENCE (2014)
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
Julian H. Elliott et al.
PLOS PATHOGENS (2014)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A. Rasmussen et al.
LANCET HIV (2014)
Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure
Ya-Chi Ho et al.
CELL (2013)
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism
Daniela Boehm et al.
CELL CYCLE (2013)
Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant
Deborah Persaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Eliminating the latent HIV reservoir by reactivation strategies Advancing to clinical trials
Thomas A. Rasmussen et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies
Susanne Eriksson et al.
PLOS PATHOGENS (2013)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics
Rutao Luo et al.
PLOS ONE (2012)
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection
Nancie M. Archin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Standing Genetic Variation and the Evolution of Drug Resistance in HIV
Pleuni Simone Pennings
PLOS COMPUTATIONAL BIOLOGY (2012)
Stochastic Theory of Early Viral Infection: Continuous versus Burst Production of Virions
John E. Pearson et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy
Jason B. Dinoso et al.
JOURNAL OF VIROLOGY (2009)
Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy
Libin Rong et al.
PLOS COMPUTATIONAL BIOLOGY (2009)
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
Nancy M. Archin et al.
AIDS (2008)
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy - a randomized trial
W. M. El-Sadr et al.
ANNALS OF INTERNAL MEDICINE (2008)
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Sarah Palmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
HIV rebounds from latently infected cells, rather than from continuing low-level replication
Beda Joos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia
Frank Maldarelli et al.
PLOS PATHOGENS (2007)
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: Final results from a randomized clinical trial (Pulse)
Mark T. Bloch et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study
G Lehrman et al.
LANCET (2005)
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
JD Siliciano et al.
NATURE MEDICINE (2003)
HIV RNA in plasma rebounds within days during structured treatment interruptions
M Fischer et al.
AIDS (2003)
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
L Ruiz et al.
AIDS (2001)
Share Paper
